X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-02 | ATHA | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $0.56 | -10,826 | 35,841 | -23% | -$6,083 | |||||
| D | 2025-01-02 | ATHA | Litton Mark James | Pres, CEO | S - Sale+OE | $0.56 | -25,107 | 262,280 | -9% | -$14,108 | |||||
| D | 2025-01-02 | ATHA | Church Kevin | Chief Scientific Officer | S - Sale+OE | $0.56 | -8,510 | 130,761 | -6% | -$4,782 | |||||
| D | 2025-01-02 | ATHA | Renninger Robert | VP of Finance | S - Sale+OE | $0.56 | -2,881 | 89,724 | -3% | -$1,619 | |||||
| D | 2025-01-02 | ATHA | Worthington Mark | GC, CCO | S - Sale+OE | $0.56 | -8,510 | 83,735 | -9% | -$4,782 | |||||
2024-09-05 | ATHA | Gengos Andrew | CFO, CHIEF BUSINESS OFFICER | S - Sale | $0.57 | -1,272 | 97,532 | -1% | -$720 | ||||||
2024-09-05 | ATHA | Lenington Rachel | COO, CDO | S - Sale | $0.57 | -2,525 | 20,870 | -11% | -$1,429 | ||||||
2024-09-05 | ATHA | Church Kevin | Chief Scientific Officer | S - Sale | $0.57 | -2,525 | 92,684 | -3% | -$1,429 | ||||||
2024-09-05 | ATHA | Worthington Mark | GC | S - Sale | $0.57 | -2,525 | 51,927 | -5% | -$1,429 | ||||||
2024-09-05 | ATHA | Litton Mark James | Pres, CEO | S - Sale | $0.57 | -5,032 | 179,054 | -3% | -$2,848 | ||||||
| M | 2024-06-21 | ATHA | Romano Kelly A | Dir | P - Purchase | $2.36 | +42,400 | 80,715 | +111% | +$100,051 | |||||
| A | 2024-01-05 | ATHA | Lenington Rachel | COO, CDO | S - Sale | $2.91 | -2,412 | 13,395 | -15% | -$7,019 | |||||
| A | 2024-01-05 | ATHA | Litton Mark James | CEO | S - Sale | $2.91 | -4,820 | 164,086 | -3% | -$14,026 | |||||
| A | 2024-01-05 | ATHA | Worthington Mark | GC | S - Sale | $2.91 | -2,412 | 34,452 | -7% | -$7,019 | |||||
| A | 2024-01-05 | ATHA | Gengos Andrew | CFO, CHIEF BUSINESS OFFICER | S - Sale | $2.91 | -1,208 | 83,804 | -1% | -$3,515 | |||||
| A | 2024-01-05 | ATHA | Church Kevin | Chief Scientific Officer | S - Sale | $2.91 | -2,412 | 80,256 | -3% | -$7,019 | |||||
2023-01-05 | ATHA | Gengos Andrew | See Below | S - Sale | $2.91 | -1,208 | 83,804 | -1% | -$3,515 | ||||||
2024-01-05 | ATHA | Litton Mark James | CEO | S - Sale | $2.91 | -4,820 | 164,086 | -3% | -$14,026 | ||||||
2024-01-05 | ATHA | Worthington Mark | GC | S - Sale | $2.91 | -2,412 | 34,452 | -7% | -$7,019 | ||||||
2023-01-05 | ATHA | Church Kevin | Chief Scientific Officer | S - Sale | $2.91 | -2,412 | 80,256 | -3% | -$7,019 | ||||||
2024-01-05 | ATHA | Lenington Rachel | COO | S - Sale | $2.91 | -2,412 | 13,395 | -15% | -$7,019 | ||||||
| M | 2023-12-27 | ATHA | Perceptive Advisors LLC | Dir, 10% | P - Purchase | $2.42 | +605,686 | 5,402,964 | +13% | +$1,462,895 | |||||
2023-06-07 | ATHA | Gengos Andrew | See Below | P - Purchase | $3.43 | +15,000 | 80,012 | +23% | +$51,445 | ||||||
| M | 2023-06-02 | ATHA | Gengos Andrew | See Below | P - Purchase | $2.95 | +65,012 | 65,012 | New | +$191,572 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |